Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure

Angiology

Volumn 65, Issue 6, 2014, Pages 533-537

  Karabacak, Mustafa ^a   Dogan, Abdullah ^b   Aksoy, Fatih ^b   Ozaydin, Mehmet ^b   Erdogan, Dogan ^b   Karabacak, Pinar ^b  

^a ISPARTA STATE HOSPITAL   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

carvedilol; d dimer; fibrinogen; heart failure; mean platelet volume; nebivolol

Indexed keywords

CARVEDILOL; D DIMER; FIBRINOGEN; NEBIVOLOL; BENZOPYRAN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; ETHANOLAMINE DERIVATIVE; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; BLOOD; DRUG COMBINATION; SINGLE BLIND PROCEDURE;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; BENZOPYRANS; CARBAZOLES; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEART FAILURE; HUMANS; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; PROPANOLAMINES; SINGLE-BLIND METHOD;

EID: 84903512074     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713489340     Document Type: Article

References (36)

1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 ; 29 (19). 2388-2442
2. Francis GS, Benedict C, Johnston DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 ; 82 (5). 1724-1729
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med. 1996 ; 334 (21). 1349-1355
4. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS). Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 ; 344 (22). 1651-1658
5. Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 ; 26 (3). 215-225
6. Doughty RN, White HD. Carvedilol: use in chronic heart failure. Expert Rev Cardiovasc Ther. 2007 ; 5 (1). 21-31
7. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000 ; 101 (5). 558-569
8. Frishman WH, Weksler B, Christodoulou JP, et al. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation. 1974 ; 50 (5). 887-896
9. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood. 1977 ; 49 (2). 185-196
10. Kerry R, Scrutton MC, Wallis RB. Beta-adrenoceptor antagonists and human platelets: relationship of effects to lipid solubility. Biochem Pharmacol. 1984 ; 33 (16). 2615-2622
11. McNeely W, Goa KL. Nebivolol in the management of essential hypertension. Drugs. 1999 ; 57 (4). 633-651
12. Falciani M, Rinaldi B, D'Agostino B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol. 2001 ; 38 (6). 922-929
13. Park Y, Schoene N, Harris W. Mean platelet volume is an indicator of platelet activation: methodological issues. Platelets. 2002 ; 13 (5-6). 301-306
14. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des. 2011 ; 17 (1). 47-58
15. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol. 1995 ; 25 (7). 1634-1640
16. Jung SC, Wilensky RL, Zeller J.. Thrombin activation in dilated cardiomyopathy. J Am Coll Cardiol. 1993 ; 21 (suppl A). 311A
17. Remme WJ. Which beta blocker is most effective in heart failure?. Cardiovasc Drugs Ther. 2010 ; 24 (4). 351-358
18. Rehsia NS, Dhalla NS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol. 2010 ; 15 (4). e86 - e95
19. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure. Results of the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 ; 362 (9377). 7-13
20. Bakovic D, Pivac N, Eterovic D. Changes in platelet. Clin Exp Pharmacol Physiol. 2009 ; 36 (4). 441-446
21. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity?. Clin Appl Thromb Hemost. 2003 ; 9 (3). 177-190
22. Martin JF Platelet Heterogeneity: Biology and Pathology. Martin JF Trowbridge EA, ed. London, UK: Springer-Verlag ; 1990: 205-226.
23. Martin JF, Trowbridge EA, Salmon GL, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983 ; 32 (5). 443-460
24. Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D. Arachidonic acid metabolism by platelets of differing size. Br J Haematol. 1983 ; 53 (3). 503-511
25. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994 ; 24 (1). 69-72
26. Jagroop IA, Mikhailidis DP. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2003 ; 120 (1). 169-170
27. Varol E, Icli A, Ozaydin M, Erdogan D, Arslan A. Mean platelet volume is elevated in patients with myocardial infarction with normal coronary arteries, as in patients with myocardial infarction with obstructive coronary artery disease. Scand J Clin Lab Invest. 2009 ; 69 (5). 570-574
28. Açkgöz N, Ermiş N, Yaǧmur J. The evaluation of mean platelet volume levels in patients with idiopathic and ischemic cardiomyopathy: an observational study. Anadolu Kardiyol Derg. 2011 ; 11 (7). 595-599
29. Ertaş G, Kozdaǧ G, Emre E, Akay Y, Ural D, Hebert K. Effect of enhanced external counterpulsation treatment on mean platelet volume in patients affected by ischemic chronic heart failure. Blood Coagul Fibrinolys. 2012 ; 23 (2). 127-131
30. Celik T, Yüksel CU, Iyisoy A. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol. 2007 ; 116 (2). 206-211
31. Cleland JGF, Swedberg K. Carvedilol for heart failure, with care. Lancet. 1996 ; 347 (9010). 1199-1201
32. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 ; 294 (14). 1799-1809
33. Danesh J, Whincup P, Walker M, et al. Fibrin d-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001 ; 103 (19). 2323-2327
34. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008 ; 14 (suppl 5). 11-26
35. Canan A, Halcioglu SS, Gurel S. Mean platelet volume and d-dimer in patients with suspected deep venous thrombosis. J Thromb Thrombolysis. 2012 ; 34 (2). 283-287
36. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study of patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997 ; 29 (1). 106-112